Professor of Medicine
Director, Am. Heart Assoc Comprehensive Hypertension Center
Chicago, IL


LEARNING OBJECTIVES
After completing this learning activity, participants will be better able to:

• Provide a recent update and clinical experience in the management of HK worldwide along with recent updates with KDIGO guidelines in the management of RAASi, in both CKD diabetes and hypertension groups.
• Review the most recent recommendations and data on new potassium binders for optimizing RAASi therapy in patients with CKD
• Discuss (describe) application of new potassium binders to enable optimal RAASi therapy in clinical practice with case-studies

George L. Bakris, MD, received his medical degree from the Chicago Medical School and completed his residency in Internal Medicine at the Mayo Graduate School of Medicine where he also did a research fellowship in Physiology and Biophysics. He then completed fellowships in Nephrology and Clinical Pharmacology at the University of Chicago.
From 1988 to 1991 he served as Director of Renal Research at the Ochsner Clinic and was a faculty member of Tulane University School of Medicine. He was also Professor and Vice Chairman of Preventive Medicine and Director of the Rush University Hypertension Center in Chicago, Illinois from 1993 until 2006.

Currently, he is Professor of Medicine and Director, ASH Comprehensive Hypertension Center in the Section of Endocrinology, Diabetes and Metabolism at the University of Chicago Medicine.
Dr. Bakris has published more than 700 articles and book chapters in the areas of kidney disease, hypertension, and progression of nephropathy.
He is the Editor or Co-Editor of 19 books, all dealing with kidney disease, diabetes, and the role of hypertension. These include: Hypertension: Principles and Practice; Handbook of Hypertension; The Kidney in Cardiovascular Disease; Therapeutic Strategies in Hypertension; The Kidney in Heart Failure and Hypertension: A Companion to Braunwald’s The Heart.
Additionally, he is the Associate Editor of the International Textbook of Cardiology. He has also served as the co-principal investigator of an NIH Clinical Research training grant to train clinical researchers (1999-2004).
He chaired the National Kidney Foundation Consensus Report on blood pressure and impact on renal disease progression (2000). He has also served on many national committees including the JNC 7 executive and writing committee (2003), the American Diabetes Association Clinical Practice Guideline committee (2003-2004), the National Kidney Foundation (K-DOQI) Blood Pressure Guideline committee (2002-2004), the National Kidney Foundation (K-DOQI) Diabetes Guideline committee (2003-2005), and the NIH National High Blood Pressure Education Program Working Group on Hypertension and Renal Disease (1994).
He also serves as a special government expert to the Cardio-renal Advisory Board of the FDA (2003-present) and CMS.
He is the current Editor of the American Journal of Nephrology and the Nephrology and Hypertension Section Editor of Up-to-Date.
He serves on more than 16 editorial boards, including Diabetes Care, Kidney International, Nephrology, Dialysis and Transplantation, Hypertension, the Journal Am Soc Hypertens, and the Journal of Hypertension.
And, he has served on many guidelines committees over the past 15 years and is currently the chair of the American Diabetes Association Blood Pressure Consensus Panel and a member of the American Heart Association panel updating resistant hypertension guidelines.
Dr. Bakris received the Irvine Page-Alva Bradley Lifetime Achievement Award to acknowledge his lifetime of outstanding achievements in the field of hypertension.

Nephrologist
Associate Professor
Chronic Disease Innovation Center
University of Manitoba
Winnipeg, MB


LEARNING OBJECTIVES
After completing this learning activity, participants will be better able to:

• Provide a recent update and clinical experience in the management of HK worldwide along with recent updates with KDIGO guidelines in the management of RAASi, in both CKD diabetes and hypertension groups.
• Identify population at risk of hyperkalemia & recognize the burden and consequences of chronic hyperkalemia on patient health

Dr. Tangri is an attending physician and Associate Professor in the Division of Nephrology, Department of Medicine and the Department of Community Health Sciences at the University of Manitoba. Dr. Tangri’s research program is clinical and translational and focused on improving clinical decision making for patients with advanced chronic kidney disease. He developed and validated the Kidney Failure Risk Equation to predict the need for dialysis in patients with CKD, and is presently engaged in multiple validation and implementation exercises to increase the uptake of the KFRE.

In addition, Dr. Tangri is conducting a large prospective study on frailty, physical and cognitive function in advanced CKD, as well as leading a multinational randomized trial on the safety and efficacy of a new therapy in this population. He has published over 200 manuscripts and presented at multiple national and international scientific meetings, and is a recipient of the CIHR New Investigator Award and a CIHR Foundation grant.